HER2/neu over-expression predicts poor outcome in early gastric cancer without lymph node metastasis - 05/02/15
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
| pagine | 6 |
| Iconografia | 2 |
| Video | 0 |
| Altro | 0 |
Summary |
Purpose |
Human epidermal growth factor receptor 2 (HER2/neu) is involved in the pathogenesis of several types of cancer, including gastric cancer. However, there remains a paucity of data regarding the prognostic relevance of HER2/neu in early gastric cancer without lymph node metastasis (pN0 EGC). The aim of our study was to analyze whether the over-expression of HER2/neu significantly predicts poor outcomes of pN0 EGC.
Patients and methods |
Sixty-seven patients who underwent operative resection for pN0 EGC was enrolled. The HER2/neu status was examined by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
Results |
The HER2/neu-positive rate was 16.4%. HER2/neu over-expression showed a significant correlation with histological type (P≤0.001), tumor location (P=0.022) and Lauren grade (P=0.012). Multivariate analysis showed HER2/neu serves as a good prognostic marker to predict the risk of poor outcome for pN0 EGC. (HR=1.384, 95.0% CI: 1.142–1.897 P=0.005)
Conclusion |
Considering HER2/neu over-expression significantly predicts poor outcome in pN0 EGC, accurate HER2/neu assessment would be done before endoscopic therapy. For HER2/neu-positive patients, radical surgery should be performed.
Il testo completo di questo articolo è disponibile in PDF.Mappa
Vol 39 - N° 1
P. 121-126 - febbraio 2015 Ritorno al numero
Articolo precedente
- Transplantation of bone marrow-derived mesenchymal stem cells facilitates epithelial repair and relieves the impairment of gastrointestinal function in a rat model of enteritis
- Bo Qu, Hai-Yan Jiang, Bei-Bei Wang, Jia-Zhao Tong, Bo Yu, Yong-Hong Zhang, Bing-Rong Liu, Fang Zhu, Shi-Zhu Jin
- Estrogen Receptor 1 (ESR1) genetic variations in cancer risk: A systematic review and meta-analysis
- Huiling Sun, Jinjun Hou, Wenbin Shi, Lei Zhang
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?